Perceived versus actual understanding of combination therapies and biomarker-driven treatment: a pan-European survey of 1,446 cancer patients

Purpose Combination therapies (CTs) and biomarker-guided treatment selection are increasingly central to oncology, yet how closely patients’ perceived understanding matches their actual understanding is unknown. We examined whether patients recognise this gap, how benefit versus harm literacy compares and how far both vary by country. Methods A 29-item anonymous survey in five languages ran for 90 days via Cancer Patients Europe networks. Individual responses were analysed, allowing items to be cross-tabulated within respondents. Proportions carry Wilson 95% CIs; the paired benefit–harm comparison uses McNemar’s test; country differences use χ 2 with Holm adjustment and multivariable logistic regression. Results Of 1446 respondents, 70.4% ( n = 1103) felt adequately informed, yet 45.9% ( n = 985) had never been told about a combination approach and 39.8% ( n = 937) did not know whether biomarker testing guided care; linked within individuals, 25.8% (95% CI 23.2–28.6) both felt adequately informed and had never been told—adequacy misclassifies about one patient in four. Patients were over three times as likely to name a benefit but no harm than the reverse (195 vs. 55 discordant pairs; McNemar P < 0.001). Country differences persisted after adjustment (Italy adjusted OR 2.09, 1.34–3.26; Germany 1.62, 1.07–2.45; reference United Kingdom). Conclusion Patient-reported information adequacy misclassifies about a quarter of patients, communication favours benefits over harms within individuals and country differences survive adjustment—locating the deficit in how systems communicate. Practice should replace satisfaction-based metrics with comprehension checks, adopt toxicity-explicit decision aids, standardise biomarker-result communication and scale advocacy-linked navigation.

Authors

Publication Details

Journal
Supportive Care in Cancer
Published
2026-11-19
DOI
https://doi.org/10.1007/s00520-026-11484-2
Primary Topic
Patient-Provider Communication in Healthcare
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Perceived versus actual understanding of combination therapies and biomarker-driven treatment: a pan-European survey of 1,446 cancer patients

Martina Garau, Frank-Ulrich Fricke, Antonella Cardone, Conchi Biurrun et al.
2 links
Supportive Care in Cancer
Patient-Provider Communication in Healthcare
article

Perceived versus actual understanding of combination therapies and biomarker-driven treatment: a pan-European survey of 1,446 cancer patients

Martina Garau, Frank-Ulrich Fricke, Antonella Cardone, Conchi Biurrun, Juan Jose Ventura³
article en

Abstract

Purpose Combination therapies (CTs) and biomarker-guided treatment selection are increasingly central to oncology, yet how closely patients’ perceived understanding matches their actual understanding is unknown. We examined whether patients recognise this gap, how benefit versus harm literacy compares and how far both vary by country. Methods A 29-item anonymous survey in five languages ran for 90 days via Cancer Patients Europe networks. Individual responses were analysed, allowing items to be cross-tabulated within respondents. Proportions carry Wilson 95% CIs; the paired benefit–harm comparison uses McNemar’s test; country differences use χ 2 with Holm adjustment and multivariable logistic regression. Results Of 1446 respondents, 70.4% ( n = 1103) felt adequately informed, yet 45.9% ( n = 985) had never been told about a combination approach and 39.8% ( n = 937) did not know whether biomarker testing guided care; linked within individuals, 25.8% (95% CI 23.2–28.6) both felt adequately informed and had never been told—adequacy misclassifies about one patient in four. Patients were over three times as likely to name a benefit but no harm than the reverse (195 vs. 55 discordant pairs; McNemar P < 0.001). Country differences persisted after adjustment (Italy adjusted OR 2.09, 1.34–3.26; Germany 1.62, 1.07–2.45; reference United Kingdom). Conclusion Patient-reported information adequacy misclassifies about a quarter of patients, communication favours benefits over harms within individuals and country differences survive adjustment—locating the deficit in how systems communicate. Practice should replace satisfaction-based metrics with comprehension checks, adopt toxicity-explicit decision aids, standardise biomarker-result communication and scale advocacy-linked navigation.

Supportive Care in CancerVol. 34(12)
Eli Lilly and Company, Pfizer, Astellas Pharma
Good health and well-being
Patient-Provider Communication in Healthcare
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon